Rather than committing a candidate to one disease area early on, they carry out studies in multiple small, focused patient populations. They then follow the science to identify patient groups who show the most promising therapeutic response. Often this leads to the exploration of rare diseases that are genetically well defined and have few effective treatment options.
We're not wedded to, nor are we held down by, our disease focus areas, so we can really concentrate on capturing emerging science and driving it towards addressing unmet needs. The small-scale studies also help streamline larger future efforts in more common diseases. They may, for example, provide critical safety and dosing information or establish biomarkers that allow us to easily detect a therapeutic response. Deeply understanding how a drug works in one disease, may allow us to predict success in other conditions. For example, fully understanding the inflammation pathways in patients with Juvenile Idiopathic Arthritis that were controlled by canakinumab, an IL-1b inhibitor, helped identify, and support, the approval in patients with Adult Onset Still's Disease.
"We're not wedded to, nor are we held down by, our disease focus areas, so we can really concentrate on capturing emerging science and driving it towards addressing unmet needs," explains Beckman. "This helps us move quickly in new directions and nimbly across disease areas."
At times, this approach dictates that clinical trials are trials in diseases without an existing roadmap. For example, designing a clinical trial in sarcopenia-the age-related loss of skeletal muscle mass and strength-was nearly impossible less than a decade ago, based on a lack of consensus on disease characteristics. "There had been no accepted definition of the patient population," says Beckman. "But the Translational Medicine leadership worked with academics and members of industry to push health authorities and expert communities to come up with some accepted definitions. These now exist for the first time in Europe. 2 " In the U.S. these efforts have led to the approval of a statistical classification code for sarcopenia as well, advancing research of the disease at Novartis and other organizations. 3, 4 Discovery [2] Turning research advances into innovative medicines [3] Footnotes:
